Conferences
ASCO GU 2018: The Importance of Tumor Heterogeneity for the Interpretation of Renal Mass Biopsy
February 11, 2018
ASCO GU 2018: Optimal Patient Selection for Active Surveillance or Ablation in Small Renal Tumors
February 11, 2018
ASCO GU 2018: Best of Journals: Prostate Cancer - Medical Oncology
February 11, 2018
ASCO GU 2018: Sentinel Node Biopsy in Clinical Stage I Testicular Cancer
February 11, 2018
Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer Announced at 2018 ASCO Genitourinary Cancers Symposium
February 11, 2018
ASCO GU 2018: Best of Journals: Urothelial Carcinoma
February 11, 2018
ASCO GU 2018: Blood-brain Barrier Penetration of [14C]-Darolutamide Compared with [14C]-Enzalutamide in Rats Using Whole Body Autoradiography
February 10, 2018
ASCO GU 2018: The impact of neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
February 10, 2018
ASCO GU 2018: Distress Prevalence and Associated Risk Factors within the Urothelial Cancer Population
February 10, 2018
ASCO GU 2018: Avelumab as Neoadjuvant Therapy in Subjects with Muscle-invasive Urothelial Carcinoma - AURA Trial
February 10, 2018
ASCO GU 2018: Immune Checkpoint Inhibitors: Which One and Why?
February 10, 2018
ASCO GU 2018: Two-year Follow-up: 3 KEYNOTE-045 Trial of Pembrolizumab vs Investigator’s Choice Chemotherapy in Recurrent, Advanced Urothelial Cancer
February 10, 2018
ASCO GU 2018: New 6-factor prognostic model for patients with advanced urothelial carcinoma receiving post-platinum atezolizumab
February 10, 2018
ASCO GU 2018: Atezolizumab vs. Chemotherapy in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma - Outcomes from the Phase III IMvigor211 Study
February 10, 2018